Aakaar Medical Technologies (NSE:AAKAAR) EBIT: ₹108.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AAKAAR Aakaar Medical Technologies Ltd NSE:AAKAAR
20 GF Score
Price ₹70.20
! 3 Warning Signs
View Full Analysis

What is Aakaar Medical Technologies EBIT?

Aakaar Medical Technologies NSE:AAKAAR -1.06% 20 EBIT is ₹108.5 Mil as of Mar. 2026. GuruFocus rates NSE:AAKAAR with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Aakaar Medical Technologies's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹108.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹108.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aakaar Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2026 was 24.62%. Aakaar Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 43.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aakaar Medical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.66%.

Aakaar Medical Technologies  (NSE:AAKAAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aakaar Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=215.354 * ( 1 - 27.35% )/( (672.963 + 598.137)/ 2 )
=156.454681/635.55
=24.62 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=711.643 - 24.376 - ( 14.304 - max(0, 229.577 - 518.926+14.304))
=672.963

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=794.166 - 33.596 - ( 162.433 - max(0, 238.83 - 766.121+162.433))
=598.137

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Aakaar Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=216.578/( ( (1.997 + max(446.202, 0)) + (1.694 + max(549.867, 0)) )/ 2 )
=216.578/( ( 448.199 + 551.561 )/ 2 )
=216.578/499.88
=43.33 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(264.94 + 191.114 + 48.568) - (24.376 + 0 + 34.044)
=446.202

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(372.252 + 197.504 + 33.598) - (33.596 + 0 + 19.891)
=549.867

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aakaar Medical Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=108.463/1017.842
=10.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aakaar Medical Technologies EBIT Related Terms

Aakaar Medical Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Aakaar Medical Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aakaar Medical Technologies EBIT Chart

Aakaar Medical Technologies Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
23.88 34.64 48.77 96.91 108.46

Aakaar Medical Technologies Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial 0.00 14.34 82.56 0.17 108.29

NSE:AAKAAR vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Aakaar Medical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aakaar Medical Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aakaar Medical Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aakaar Medical Technologies's EV-to-EBIT falls into.


NSE:AAKAAR
20GF Score
Aakaar Medical Technologies Ltd NSE:AAKAAR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aakaar Medical Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹108.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹108.5 Mil mean?
Aakaar Medical Technologies (NSE:AAKAAR) has a EBIT of ₹108.5 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aakaar Medical Technologies.
Is Aakaar Medical Technologies' EBIT too high?
Aakaar Medical Technologies' current EBIT is ₹108.5 Mil. Overall, Aakaar Medical Technologies has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Aakaar Medical Technologies' EBIT compare to ABT and SYK?
Aakaar Medical Technologies' EBIT of ₹108.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aakaar Medical Technologies. Aakaar Medical Technologies's current EBIT is ₹108.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aakaar Medical Technologies stock overvalued right now?
Aakaar Medical Technologies (NSE:AAKAAR) has a current EBIT of ₹108.5 Mil. The current EBIT is ₹108.5 Mil. Aakaar Medical Technologies' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aakaar Medical Technologies (NSE:AAKAAR), the current EBIT is ₹108.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aakaar Medical Technologies Business Description

Address Telli Galli Cross Road, A - 801, Heritage Plaza, Andheri East, Mumbai, MH, IND, 400 069
Aakaar Medical Technologies Ltd is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It has established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business(B2B) channels for product distribution and sales. The company supply its products & devices to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments.
20GF Score

Get the complete analysis for NSE:AAKAAR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹70.20
Price